<DOC>
	<DOCNO>NCT02264743</DOCNO>
	<brief_summary>Ultra-low-dose oral E2/D beneficial effect trans-dermal HRT lipid insulin resistance postmenopausal woman , whilst adverse effect coagulation avoid .</brief_summary>
	<brief_title>Oral Verses Patch Trial In Menopausal Women - Individualisation Oestrogen Therapy</brief_title>
	<detailed_description>Following screen eligibility , woman study baseline randomize one two group : Group A administer Femoston Conti - oral oestradiol 17β 0.5 mg/dydrogesterone 2.5 mg daily duration treatment phase ( 24 week ) Group B administer ½ Evorel Conti patch - trans-dermal Estradiol 25 mcg/norethisterone acetate 85 mcg ( ½ Evorel Conti patch ) daily duration treatment phase ( 24 week ) . Studies repeat 6 month therapy follow visit .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Healthy postmenopausal woman normal ultrasound result Aged 40 60 year At least 1 year post last menstrual period ( per participant report ) BMI 18 32 Normal mammogram within 2 year study commencement Continue concomitant medication without change study give inform consent Estrogen androgen therapy precede 3 month Use hormone implant precede 12 month Have receive medication may interfere study ( SSRI , antiandrogens , PDE5 inhibitor , DHEA , SERMS ) Have significant psychiatric disorder Have history breast oestrogen dependent cancer Have diabetes , thromboembolic disorder ( recent MI angina DVT varicose vein recurrent DVT ) , cardiovascular disease , liver disease condition affect carbohydrate metabolism , uncontrolled hypertension uncontrolled hyperlipidaemia Untreated endometrial hyperplasia DubinJohnson syndrome Rotor syndrome Undiagnosed vaginal bleeding Women hysterectomy</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>